Learn about emerging treatments for metastatic prostate cancer. We’ve got it covered, from new FDA approvals to emerging approaches in hormone therapy, radiation, surgery, bone-protective treatments, immunotherapy, and more.

  • July 28, 2021  

    2021 ASCO Annual Meeting Bookmark

    George Lundberg, MD

    Researchers at the 2021 annual meeting of the American Society of Clinical Oncology (ASCO) reported substantial advances in treatment for advanced esophageal, castration-resistant prostate, and metastatic nasopharyngeal cancers.

    .

  • December 3, 2020  

    Olaparib Granted Positive EU Opinion for BRCA1/2+ Advanced Prostate Cancer Bookmark

    George Lundberg, MD

    A news story published by OncLive reports that the European Union’s Committee for Medicinal Products for Human Use recently approved the drug olaparib for treating patients with a subset of advanced castrate-resistant prostate cancers that have BRCA1/2 mutations.

    .

    • SEE ALL
I learned more about my trial options from Emma in a week than I did in 3 years of previous care. Every metastatic patient should know about Cancer Commons. And I love how they use the data to speed up the N-of-1 success stories.

Michelle Kendall
Cancer Patient

Molecular tests help match patients to the personalized treatments that are most likely to work for them. Keep up with new developments in molecular testing that could help guide prostate cancer treatment, such as detection of genetic mutations and other biomarkers.

  • February 11, 2020  

    Carcinoma of Unknown Primary Case Reviewed in Tumor Board Session Bookmark

    George Lundberg, MD

    Article from CAP Today curated by Editor in Chief George Lundberg, MD, who notes: 

    Tumor boards are an established method of dealing with problem cancer cases. In precision oncology, they may, even must, be molecular. This is a great example of how a molecular tumor board can provide actionable insights for patients.

    Go to full article published by CAP Today.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • October 8, 2018  

    Accuracy and Precision Define Radiation Oncology

    With: Eddy Yang, MD, PhD

    A Q&A with Eddy Yang, MD, PhD, Professor and Vice Chair of Translational Sciences Department of Radiation Oncology; Deputy Director, Associate Director of Precision Oncology at the Hugh Kaul Precision Medicine Institute; Birmingham, AL; shyang@uabmc.edu Originally published December 5, 2017 Q: You are a radiation oncologist with a particular interest in cancer of the prostate. How does the molecular study of prostate, as well… Read more »

    • SEE ALL

Some of the most promising new treatments for metastatic prostate cancer are currently being tested in patients enrolled in clinical trials. We help you stay up to date on the latest results from these studies.

  • March 7, 2019  

    Targeted Radiation Therapy Yields High Response Rates in Metastatic Prostate Cancer Bookmark

    Emma Shtivelman, PhD

    Excerpt:

    “The targeted radiation therapy Lutetium-177 PSMA-617 produced high response rates among men with prostate-specific membrane antigen-positive metastatic, castration-resistant prostate cancer, according to results of a single-arm, phase 2 trial scheduled for presentation at Genitourinary Cancers Symposium.

    “The treatment also appeared well-tolerated among these men, whose disease had progressed after multiple standard therapies.”

    Go to full article published by Healio on Feb 14, 2019.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • October 22, 2018  

    The Link Between Apalutamide and QOL in Non-Metastatic CRPC Bookmark

    Emma Shtivelman, PhD

    Excerpt:

    “Adding apalutamide to androgen deprivation therapy (ADT) does not appear to harm health-related quality of life (HRQOL) in men with nonmetastatic castration-resistant prostate cancer (CRPC), according to new research published in Lancet Oncology.

    “Previous research has showed that men in this patient population who received apalutamide had longer metastasis-free survival and a longer time to symptomatic progression compared with those who received placebo. This new study found that adding apalutamide still preserves HRQOL. Specifically, the group mean patient-reported outcome scores over time demonstrated HRQOL was maintained from baseline (initiation of apalutamide), and it was similar over time among men receiving apalutamide versus placebo.”

    Go to full article published by Cancer Network on Oct 9, 2018.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

    • SEE ALL
In a field as complex and dynamic as molecular oncology in 2020, Cancer Commons offers an amazing opportunity for patients with advanced cancer to obtain scientifically up-to-date additional options that may improve both the length and quality of their lives, all free of charge.

Gavin Gordon, PhD
Molecular Pathologist

Cancer affects many aspects of life, whether you’re newly diagnosed, in the midst of treatment, or in follow-up care. Learn about ways to maintain quality of life, such as palliative care and managing side effects.

  • August 11, 2021  

    Anxiety Before Each Chemotherapy Treatment Bookmark

    Lola Rahib, PhD

    Article from Let’s Win! Pancreatic Cancer: Pancreatic cancer patients share their experiences with pre-chemo anxiety and their personal strategies for overcoming it.

    .

  • February 11, 2020  

    ‘Impressed With Impact’ of Ketamine in Cancer Palliative Care Bookmark

    George Lundberg, MD

    Article from Medscape curated by Editor in Chief George Lundberg, MD, who notes: 

    Depression is, for obvious reasons, common in patients with advanced cancer. The old, inexpensive drug ketamine—already approved for medical use by the U.S. Food and Drug Administration (FDA)—seems rapidly effective, according to small studies.

    Go to full article published by Medscape.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

    • SEE ALL

You’re not alone. Read how other patients and caregivers navigated diagnosis, treatment, and life with cancer. We hope their stories provide insights and hope for your own cancer journey.

More patient stories

Learn more about what’s new in advanced cancer research and treatment, including screening and statistics, using artificial intelligence to improve treatment, and other new horizons in cancer care.

  • May 30, 2021  

    Cancer Support for LGBTQIA Patients Is Missing Bookmark

    George Lundberg, MD

    This piece from ASCO Connection outlines the need for and a path to improvement in cancer care for LGBTQIA patients.

    .

  • April 7, 2021  

    Rankings of Most Common and Deadly Cancer Types Will Shift Over Next Two Decades

    In the next two decades, rankings of incidence and death across cancer types will undergo important changes in the U.S., according to new research led by Lola Rahib, PhD, Director of Scientific and Clinical Affairs at Cancer Commons, as well as the Pancreatic Cancer Action Network (PanCAN) in collaboration with The University of Texas MD Anderson Cancer Center. Published today in JAMA Network Open,… Read more »

    • SEE ALL

The coronavirus pandemic presents unprecedented challenges to cancer patients. We can help you understand how COVID-19 might impact your treatment and other aspects of your cancer care.